Organ-on-a-Chip Resources

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.

PhysioMimix Bioavailability assay kit: Human 18 brochure

Modernize your workflow with the only in vitro bioavailability assessment tool on the market. Elevate your workflow with our all-in-one Bioavailability assay kit containing everything you need to recreate our human in vitro Gut/Liver-on-a-chip model and Bioavailability assay in your laboratory.

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

A Gut/Liver microphysiological system for profiling human oral bioavailability

Webinar Series 7 Episode 4

Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?

Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability. However, as with any model system, Caco-2 cells have their own set of limitations. This raises important questions: Do their limitations undermine their gold-standard status? Is it time to improve estimations with more physiologically relevant approaches? What new approaches are available, and most importantly, do their benefits sufficiently outweigh the effort required to adopt a new approach?

6 Challenges in ADME Drug Development

Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS

Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut^® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.

How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials

This blog explores a world where novel multi-organ in vitro models, tiny replicas of the human intestine and liver, provide the key to unlocking a deeper understanding of how we Absorb, Distribute and Metabolize drugs.

Read more to discover why accurately estimating human ADME remains a challenge and a potential solution that enables greater confidence in lead candidates and a reduced risk of identifying poor oral bioavailability during first in human studies.

Connecting the gut and liver

A human-relevant dual-organ microphysiological system connecting the gut and liver for preclinical profiling of oral bioavailability

Discover a new PhysioMimix® microphysiological system (MPS) that connects primary human RepliGut® and liver models to overcome the limitations of preclinical drug ADME profiling. Download the Application Note to explore the MPS’ evaluation of Temocapril and Midazolam, demonstrating its ability to provide more accurate predictions and change the risk calculus for safer and more efficient drug development.

Connecting the human intestine and liver

A primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability

Traditional immortalized intestinal cell lines and suspension hepatocytes have absent or low levels of metabolic enzyme expression, and thus fail to predict first pass human metabolism and oral bioavailability.

Efforts to improve the in vitro to in vivo translation of drug efficacy and safety data has led to the emergence of more human relevant microphysiological systems (MPS) that consist of multiple, fluidically linked organs¹.